Bolt throws a wrench in the pipeline, look­ing to con­serve cash

A melt­down in the biotech mar­ket is mak­ing most ex­ecs cau­tious, in­clud­ing Bolt Bio­ther­a­peu­tics’ CEO, as the com­pa­ny hits the brakes on one pre­clin­i­cal as­set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER